Epstein–Barr virus peptide-major histocompatibility complex (EBV pMHC)

Epstein–Barr virus (EBV) peptide-major histocompatibility complex (pMHC) refers to the presentation of viral protein fragments on the surface of infected cells by MHC class I or II molecules (Source 1.2.4, 1.4.1). These complexes are the essential recognition units for the host's cellular immune system, particularly CD8+ and CD4+ T cells, which identify and eliminate EBV-infected cells (Source 1.3.1). In the context of EBV-associated malignancies—such as post-transplant lymphoproliferative disorder (PTLD), nasopharyngeal carcinoma, and certain lymphomas—the virus expresses specific latent antigens (e.g., LMP1, LMP2, EBNA1) that form these pMHC targets (Source 1.1.1, 1.4.3). Therapeutic interventions like tabelecleucel (Ebvallo) and various T-cell receptor (TCR)-engineered T-cell therapies are designed to specifically bind these complexes to trigger a targeted cytotoxic response (Source 1.3.2, 1.4.4). However, the virus often employs immune evasion strategies, such as downregulating MHC expression or inhibiting antigen processing, which can limit the efficacy of these treatments (Source 1.1.4, 1.2.3). Monitoring patient HLA types and viral DNA load is crucial for selecting appropriate therapies and assessing clinical response (Source 1.1.5, 1.3.2).

Other names

EBV-specific peptide-MHC complexEBV-MHCEpstein-Barr virus antigen-MHC complexEBV pMHC complex

Drugs targeting this complex, such as adoptive T-cell therapies, utilize T-cell receptors (TCRs) to recognize specific viral peptides presented by MHC molecules on the surface of infected cells. This recognition triggers the activation of cytotoxic T-lymphocytes (CTLs), leading to the release of perforin and granzymes, which induce apoptosis in the target cell (Source 1.3.1, 1.4.1).